The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.
Riedl JM, Posch F, Prager G, Eisterer W, Oehler L, Sliwa T, Wilthoner K, Petzer A, Pichler P, Hubmann E, Winder T, Burgstaller S, Korger M, Andel J, Greil R, Neumann HJ, Pecherstorfer M, Philipp-Abbrederis K, Djanani A, Gruenberger B, Laengle F, Wöll E, Gerger A.
Riedl JM, et al. Among authors: prager g.
Ther Adv Med Oncol. 2020 Apr 10;12:1758835919900872. doi: 10.1177/1758835919900872. eCollection 2020.
Ther Adv Med Oncol. 2020.
PMID: 32313566
Free PMC article.